Molecular structure of Dexrazoxane, CAS Number: 24584-09-6
Dexrazoxane (CAS 24584-09-6)
See product citations (1)
Alternate Names:
(+)-(S)-4,4′-Propylenedi-2,6-piperazinedione; (S)-(+)-1,2-Bis(3,5-dioxopiperazin-1-yl)propane; Cardioxane
Application:
Dexrazoxane is an inhibitor of Topo II
CAS Number:
24584-09-6
Purity:
≥98%
Molecular Weight:
268.27
Molecular Formula:
C11H16N4O4
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Dexrazoxane, also referred to as ADR-529, is an organo-metallic compound widely employed in scientific research. It inhibits Topo II (DNA topoisomerase II) without inducing DNA strand breaks. Dexrazoxane is a (+)enantiomer of razoxane (sc-253425). Dexrazoxane also decreases formation of reactive oxygen species (ROS) and activates the PI3K/Akt survival pathway. Furthermore, dexrazoxane is thought to inhibit the activity of topoisomerase II.
Dexrazoxane (CAS 24584-09-6) References
- Dexrazoxane : a review of its use for cardioprotection during anthracycline chemotherapy. | Cvetković, RS. and Scott, LJ. 2005. Drugs. 65: 1005-24. PMID: 15892593
- Dexrazoxane: how it works in cardiac and tumor cells. Is it a prodrug or is it a drug? | Hasinoff, BB. and Herman, EH. 2007. Cardiovasc Toxicol. 7: 140-4. PMID: 17652819
- Dexrazoxane for anthracycline extravasation. | Langer, SW. 2007. Expert Rev Anticancer Ther. 7: 1081-8. PMID: 18028016
- [Dexrazoxane in anthracycline induced cardiotoxicity and extravasation]. | Goey, AK., et al. 2010. Ned Tijdschr Geneeskd. 154: A1155. PMID: 20619024
- Dexrazoxane for the prevention of cardiac toxicity and treatment of extravasation injury from the anthracycline antibiotics. | Doroshow, JH. 2012. Curr Pharm Biotechnol. 13: 1949-56. PMID: 22352729
- Dexrazoxane: a management option for anthracycline extravasations. | Vidall, C., et al. Br J Nurs. 22: S6 -12. PMID: 24067273
- Dexrazoxane for the treatment of chemotherapy-related side effects. | Langer, SW. 2014. Cancer Manag Res. 6: 357-63. PMID: 25246808
- Dexrazoxane: a cardioprotectant for pediatric cancer patients receiving anthracyclines. | Wu, V. 2015. J Pediatr Oncol Nurs. 32: 178-84. PMID: 25366577
- Dexrazoxane Alleviated Doxorubicin-Induced Nephropathy in Rats. | Hu, H., et al. 2022. Pharmacology. 107: 206-215. PMID: 35021174
- Dexrazoxane in the prevention of doxorubicin-induced cardiotoxicity. | Seifert, CF., et al. 1994. Ann Pharmacother. 28: 1063-72. PMID: 7803884
- Dexrazoxane. A review of its use as a cardioprotective agent in patients receiving anthracycline-based chemotherapy. | Wiseman, LR. and Spencer, CM. 1998. Drugs. 56: 385-403. PMID: 9777314
- Dexrazoxane (ICRF-187). | Weiss, G., et al. 1999. Gen Pharmacol. 32: 155-8. PMID: 9888268
Inhibitor of:
β-Arrestin-1, A630018P17Rik, EXOSC2, Peroxin 10, Top3, Topo II, and Topo IIIβ.Activator of:
TDP2.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Dexrazoxane, 5 mg | sc-252669 | 5 mg | $112.00 |